Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (23715)	11/3/2016 3:30:41 PM
From: Goose94	Respond to of 202988

GEC-Cse Texas Tunnel Spread.

To: Goose94 who wrote (23715)	11/8/2016 2:22:44 PM
From: Goose94	Read Replies (1) \| Respond to of 202988

Genovation Capital (GEC-Cse) Nov 4, '16 New board and management Effective on the closing of the transaction, Chris Cooper, Leslie van Santen and Michael Wystrach resigned as directors of the company, and they were replaced by Valens Agritech appointees Dave Gervais and Tim Tombe. Existing Genovation Capital directors John Binder, Tyler Robson and Robert van Santen remain on the reconstituted five-member board. The Genovation Capital board has appointed Gordon Fretwell, outside legal counsel, as corporate secretary. Robert van Santen remains as chief executive officer and chairman of the board, with Annie Storey as chief financial officer. The directors, officers and key employees of Valens Agritech, the company's wholly owned subsidiary, consist of Mr. Gervais, president and director; Mr. Tombe, corporate secretary and director; Mr. Robson, director of operations; and Yasantha Athukorala, chief scientific officer. "We have taken a first but steady step towards building out our capability and exposure to the rapidly growing medical marijuana industry," said Rob van Santen, chairman and CEO of Genovation. "With the talent and operational experience of the Valens Agritech team, we are well positioned to help advance clinical research on cannabis, introduce new products, services and additional innovations for patients and consumers, and to capitalize on our sizable investment in the Arizona-based expansion of MKHS LLC." The company intends to undergo a name change that captures its unique branding opportunity and that is more descriptive of its initiatives and strategic game plan with cannabis in the life sciences sector, subject to regulatory approval, in due course. On behalf of the Board of Directors, GENOVATION CAPITAL CORP. (signed) "Robert van Santen" Chief Executive Officer For further information, please contact: Greg Patchell, Manager, Public Relations Telephone: +1.250.860.8634 genovationcapital.ca